uniQure (NASDAQ:QURE) Short Interest Update

uniQure (NASDAQ:QURE) was the target of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 3,350,000 shares, a drop of 41.5% from the October 15th total of 5,730,000 shares. Based on an average daily trading volume, of 661,400 shares, the days-to-cover ratio is currently 5.1 days. Approximately 7.4% of the shares of the stock are short sold.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in QURE. abrdn plc lifted its stake in uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the last quarter. Acadian Asset Management LLC increased its holdings in uniQure by 133.1% in the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after purchasing an additional 350,291 shares during the period. FMR LLC increased its holdings in uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares during the period. Ikarian Capital LLC increased its holdings in uniQure by 198.1% in the first quarter. Ikarian Capital LLC now owns 469,133 shares of the biotechnology company’s stock valued at $2,439,000 after purchasing an additional 311,768 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in uniQure in the second quarter valued at $815,000. 78.83% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on QURE. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 target price on shares of uniQure in a research report on Wednesday, November 6th. StockNews.com raised uniQure to a “sell” rating in a research note on Thursday, October 17th. The Goldman Sachs Group reduced their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th. Raymond James restated an “outperform” rating and issued a $20.00 price target on shares of uniQure in a report on Thursday, October 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of uniQure in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $17.00.

uniQure Stock Performance

NASDAQ QURE traded up $0.07 during trading on Wednesday, reaching $6.80. 635,465 shares of the company’s stock were exchanged, compared to its average volume of 1,402,308. The business has a 50 day moving average price of $5.83 and a 200-day moving average price of $5.88. The stock has a market capitalization of $331.43 million, a P/E ratio of -1.37 and a beta of 0.90. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $11.35.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Sell-side analysts forecast that uniQure will post -3.81 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.